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Abstract
Somatostatin is a neuropeptide that is widely distributed
throughout the body. It acts as a neurohormone and a
neurotransmitter and may also have an immuno-
modulatory role. The genes for five subtypes of somato-
statin receptors (sst) have been cloned, suggesting that the
diverse eVects of the peptide might be mediated by
diVerent receptors.
We are interested in studying the role of sst in
inflammation, using an animal model. Because of the
up-regulation of sst expression in inflamed joints in
human rheumatoid arthritis, we chose rat adjuvant
arthritis as an experimental model. In order to
determine which of the sst subtypes might be important
in immune modulation, subtype expression in leukocytes
isolated from diVerent lymphoid tissues of the rat was
studied. Also, the expression levels of the most
abundantly expressed sst mRNAs in leukocytes from
spleen and blood were compared in rats with adjuvant
arthritis and controls, using a semi-quantitative approach.
Furthermore, the eVect of systemic administration of a
long-acting somatostatin analogue, octreotide, which
binds selectively to sst subtypes 2 and 5 (sst2 and sst5), on
the incidence and the severity of rat adjuvant arthritis, was
studied.
The main sst expressed in cells of the rat immune
system, both resting and activated, were found to be sst3
and sst4. This contrasts with the human and murine
situations, in which sst2 appears to be the main subtype
expressed in the immune system. No quantitative diVer-
ences in sst subtype mRNA levels in leukocytes from
spleen and blood were found between rats with adjuvant
arthritis and controls. Finally, no eVect of systemic admin-
istration of octreotide on either the incidence or severity of
adjuvant arthritis in Lewis rats was found. As octreotide
binds selectively to sst2 and sst5, the absence of an
immunomodulatory eVect of this analogue in rat adjuvant
arthritis corroborates our finding that these sst subtypes are
not expressed in cells of the rat immune system. In
conclusion, cells of the rat immune system appear to
express a spectrum of sst (sst3 and sst4) diVerent from that
found in human granulomatous and autoimmune disease
(mainly sst2). Therefore, the rat adjuvant arthritis model
appears to be suitable only for studying the immuno-
modulatory eVects of somatostatin analogues which have a
high aYnity for sst3 and sst4, but not for studying the
immunomodulatory eVects of octreotide, which has a high
aYnity only for sst2 and sst5.
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Introduction
Somatostatin is a neuropeptide that is widely distributed
throughout the body. It was first identified as a growth
hormone release-inhibiting factor synthesised in the
hypothalamus. Outside the central nervous system, the
peptide is present in a variety of endocrine and non-
endocrine tissues, and it appears to have many functions.
In the central nervous system it can act as a neurotrans-
mitter and neurohormone, while in peripheral tissues it
regulates endocrine and exocrine secretion and acts as a
modulator of motor activity in the gastrointestinal tract
(Reichlin 1983, Brazeau 1986). There is also increasing
evidence that somatostatin can have immunomodulatory
actions (for a review see Van Hagen et al. (1994a)).
Specific receptors (sst) for somatostatin have been iden-
tified in lymphoid tissues and on the surface of various
white blood cells and cell lines by classic ligand-binding
studies (Van Hagen et al. 1994a). In addition it was found,
in a number of granulomatous (i.e. sarcoidosis) and
autoimmune diseases (i.e. Graves’ ophthalmopathy and
rheumatoid arthritis), that sites of active inflammation
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could be visualised after the administration of an isotope-
coupled somatostatin analogue (Van Hagen et al. 1994b,c).
Since we are interested in studying the role of sst in such
inflammatory diseases, we decided to use an animal model.
Because of the up-regulation of sst expression in inflamed
joints in human rheumatoid arthritis (Reubi et al. 1994,
Van Hagen et al. 1994c), we specifically chose rat adjuvant
arthritis as an experimental model (for a review, see
Wauben et al. (1994)). The low numbers of leukocytes
that can be obtained from the joints of rats with adjuvant
arthritis prohibit analysis of the sst subtypes expressed by
these cells. However, as adjuvant arthritis is considered to
be a systemic disease in which the causative agent dissemi-
nates throughout the tissues of the body (Van Arman 1976,
Vernon-Roberts et al. 1976, Kleinau et al. 1995), an
experimental approach was set up to study the sst subtype
expression in leukocytes isolated from lymphoid organs
and peripheral blood of rats with adjuvant arthritis and
controls. We also made a comparison of the expression
levels of the most abundantly expressed sst mRNAs in
leukocytes from spleen and blood of rats with adjuvant
arthritis and controls, using a semi-quantitative approach.
Furthermore, we studied the eVect of systemic admin-
istration of a long-acting somatostatin analogue, octreotide,
which binds specifically to sst subtypes 2 and 5 (sst2 and
sst5), on the incidence and the severity of rat adjuvant
arthritis, as somatostatin has been shown to have beneficial
eVects in human rheumatoid arthritis (Coari et al. 1995).
Materials and Methods
Animals
Female Lewis rats (Harlan Sprague–Dawley, Bicester,
UK), 7–8 weeks of age, were used. The animals were kept
under clean conventional conditions with free access to
pelleted food and water in the animal facilities of the
Department of Immunology. The experimental protocol
was approved by the Animal Welfare Committee of
Erasmus University.
Induction of adjuvant arthritis
In order to induce adjuvant arthritis, rats were injected i.d.
in the base of the tail with 1 mg of a suspension of
heat-killed Mycobacterium tuberculosis strain H37 RA (Difco
Laboratories, Detroit, MI, USA) in incomplete Freund’s
adjuvant (IFA) (Difco), prepared by grinding in a mortar,
as described by Wauben et al. (1994). This preparation will
be further referred to as complete Freund’s adjuvant
(CFA). Control rats were injected with IFA only.
Preparation of cell suspensions
In order to study the sst subtype expression in rats in an
inflammatory versus a non-inflammatory state, adjuvant
arthritis was induced in ten rats, as described above. Ten
control rats were injected with IFA only. The rats were
killed by decapitation 3 weeks after injection, at peak
inflammation. Cell suspensions were prepared as described
below for analysis by reverse transcription polymerase
chain reaction (RT-PCR).
Peripheral blood Peripheral blood was collected in
polypropylene tubes containing 100 IE heparin (Leo
Pharmaceutical Products BV, Weesp, The Netherlands).
Peripheral blood mononuclear cells (PBMC) were purified
by density centrifugation on Ficoll-Paque, density=
1·077 kg/l (Pharmacia, Uppsala, Sweden). PBMC from
rats within one experimental group were pooled.
Lymphoid organ cell suspensions Spleen, thymus and
peripheral lymph nodes (popliteal, inguinal and axillary
nodes) were removed from the animals and cell suspen-
sions were prepared in RPMI 1640 medium (Gibco BRL,
Grand Island, NY, USA) supplemented with 10% fetal calf
serum (FCS) by pressing the organs through nylon gauze
(mesh size 100 µm).
Erythrocytes were depleted from the spleen cell suspen-
sion by hypotonic lysis in a 10 mM KHCO3 buVer
(pH 7·4) supplemented with 155 mM NH4Cl and
100 mM EDTA (3 ml per spleen). After 3 min at 4 )C, the
cells were washed twice in RPMI 1640 medium with 10%
FCS. Half of the total lymph node suspension was used to
prepare a non-adherent cell fraction by passage over nylon
wool (Leuko-Pak, Fenwall Laboratories, Deerfield, IL,
USA).
The diVerent cell populations were pooled per exper-
imental group. The cells were washed in ice-cold PBS,
pelleted and stored as dry pellets at "80 )C.
RNA isolation and cDNA reaction
PolyA+ mRNA was isolated from the cells using para-
magnetic oligo(dT) beads (Dynabeads Oligo(dT)25, Dynal
AS, Oslo, Norway) according to the manufacturer’s
instructions. The polyA+ mRNA was eluted in 30 µl
diethyl pyrocarbonate-treated water. All mRNA prepar-
ations were treated with deoxyribonuclease I (Amplifi-
cation Grade, Gibco) for 15 min at room temperature in
the buVer provided with the enzyme. The reaction was
stopped by the addition of 2·5 mM EDTA followed by
heating at 65 )C for 10 min.
mRNA was extracted from 107 cells in the case of
mixed cell populations (spleen, thymus, total lymph node
cells) and 2#106 cells in the case of more purified cell
populations (PBMC and lymph node non-adherent cells).
Complementary DNA (cDNA) synthesis was per-
formed starting with one-third of the isolated mRNA.
Random hexamer primers were used to ensure that all
RNA was represented equally in the cDNA pool (Tan &
Weis 1992). The reaction mixture contained 50 mM
A M C TEN BOKUM and others · Somatostatin receptor subtypes in rat immune cells168
Journal of Endocrinology (1999) 161, 167–175
Tris–HCl buVer, pH 8·3, 10 mM MgCl2, 50 mM KCl,
1 mM dithiothreitol, 1 mM EDTA, 10 µg/ml BSA, 1 mM
salmon spermine HCl (Sigma Chemical Co., St Louis,
MO, USA), 1 mM of each of the four deoxynucleotide
triphosphates (DNA Polymerisation Mix, Pharmacia),
20 U of RNA Guard (Pharmacia), 0·02 optical
density units (dN)6 (Pharmacia), 0·2 µg oligo(dT)12–18
(Boehringer Mannheim, Mannheim, Germany) and 5 U
reverse transcriptase (from avian myeloblastoma virus;
Promega, Madison, WI, USA) in a total reaction volume
of 20 µl. The reaction mixture was incubated at 41 )C for
1 h and the reaction was stopped by heating at 75 )C for
10 min. Each cDNA reaction was carried out in duplicate.
Controls
To ascertain that no genomic DNA was present in the
polyA+ preparations (which would give false-positive
signals upon amplification, as sst genes do not contain
introns), the cDNA reactions were also performed once
without reverse transcriptase (negative control samples).
These negative control samples never yielded positive
signals on amplification.
cDNA from the GH3 rat pituitary cell line was used as
a positive control for sst1 mRNA expression and cDNA
from the transplantable prolactin-secreting rat pituitary
tumour 7315b as a positive control for sst2 mRNA
expression (Visser-Wisselaar et al. 1997). Rat genomic
DNA, isolated by lysis of rat splenocytes in PCR buVer,
was used as a positive control in the PCR reactions for
sst3–5.
The PCR reactions were optimised to detect at least 104
copies of the sequence of interest (corresponding to 0·1 µg
genomic DNA) in ethidium bromide-stained gels. If, in a
particular series of PCR reactions, 104 copies of genomic
DNA after amplification did not give a clear signal in
ethidium bromide-stained gel, the series was discarded.
PCR
One-tenth of the synthesised cDNA was used for each
PCR reaction. The reaction mixture consisted of 10 mM
Tris–HCl buVer, pH 9·0, 50 mM KCl, 1·5 mM MgCl2,
0·01% (w/v) gelatine, 0·1% (v/v) Triton X-100, 0·05 mM
of each of the four deoxynucleotide triphosphates (DNA
Polymerisation Mix; Pharmacia), 5 pmol each of the
forward and reverse primers specific for one of the five rat
sst subtypes or for the â-actin gene, and 1 U AmpliTaq
DNA polymerase (Perkin-Elmer-Cetus, Norwalk, CT,
USA). PCR reactions for all primer pairs were performed
with each of the duplicate cDNA samples and positive and
negative control samples.
The primers specific for the human sst1 and sst2 as
described by Wulfsen et al. (1993) and for sst3–5 as
described by Kubota et al. (1994), were modified by us to
match the rat sequences (Meyerhof et al. 1991, 1992,
Bruno et al. 1992, Kluxen et al. 1992, Li et al. 1992,
Yasuda et al. 1992). The rat â-actin primers were as
described by Vidal et al. (1994). sst1 forward 5*-ATGGTG
GCCCTCAAGGCCGG-3*, reverse 5*-GGCAGTGGC
GTAGTAGTCAA-3* (product size 318 bp); sst2 forward
5*-TCCTCTGGGATCCGAGTGGG-3*, reverse 5*-TT
GTCCTGCTTACTGTCGCT-3* (product size 332 bp);
sst3 forward 5*-TGCCAGTGGGTACAGGCACC-3*,
reverse 5*-CTGGAGGGCCAGACCCTGGC-3* (prod-
uct size 328 bp); sst4 forward 5*-TGCGGGCTGGCTGG
CAACAA-3*, reverse 5*-GTAGTCCAGGGGCTCTT
CCT-3* (product size 311 bp); sst5 forward 5*-AGCCT
TCATCACCTACACGT-3*, reverse 5*-GGCCAGGT
TGACGATGTTGA-3* (product size 226 bp); â-actin
forward 5*-TCATGCCATCCTGCGTCTGGACCT-3*,
reverse 5*-CCGGACTCATCGTACTCCTGCTTG-3*
(product size 582 bp).
The reactions were carried out in a DNA thermal cycler
(Perkin-Elmer-Cetus). After an initial denaturation for
5 min at 94 )C, the samples were subjected to 35 cycles
(â-actin) or 40 cycles (sst subtypes) of denaturation at
94 )C for 1 min, annealing at 59 )C (â-actin and sst1–4) or
55 )C (sst5) for 2 min and extension at 72 )C for 1 min.
These numbers of cycles had previously been shown to lie
within the linear range of the reaction. After a final
extension phase of 10 min at 72 )C, 40 µl aliquots of the
amplified products were analysed on 2% agarose gels
stained with ethidium bromide. Weak bands were con-
firmed by hybridising Southern blots of the PCR products
with subtype-specific oligonucleotide probes.
For semi-quantitative comparison of the amount of
mRNA, a limiting dilution RT-PCR method was used
(Kincy-Cain & Bost 1997). Briefly, 2-fold serial dilutions
of the cDNA preparations were normalised to give
approximately equal â-actin signals, before performing
PCR for the sst subtypes. The linearity of the dilution
series was assessed by scanning the photographs of the
ethidium bromide-stained gels and determining the in-
tensity of the bands (Koning et al. 1995). For the most
accurate quantification, care was taken to include a
dilution of which the â-actin signal was no longer
visible when analysed on ethidium bromide-stained gel.
Comparisons were based on this dilution and the two
preceding it.
Receptor saturation curves
The radioligands used in the binding studies were
[125I-Tyr3]-octreotide and [125I-Tyr0]-somatostatin-28.
[Tyr3]-octreotide was iodinated and HPLC purified as
described previously (Bakker et al. 1990). [125I-Tyr0]-
somatostatin-28 was purchased from ARC-Biotrend
(Cologne, Germany). Reaction conditions were the same
as described by Reubi (1985). Briefly, cell membrane
preparations (corresponding to 15–30 µg protein) were
incubated at room temperature for 60 min with increasing
Somatostatin receptor subtypes in rat immune cells · A M C TEN BOKUM and others 169
Journal of Endocrinology (1999) 161, 167–175
concentrations of radioligand in a total volume of 100 µl
Hepes buVer (10 mM Hepes, 5 mM MgCl2 and 0·2 g/l
bacitracin, pH 7·6) containing 0·2% (w/v) BSA. After the
incubation, 1 ml ice-cold Hepes buVer was added to the
assay mixture and membrane-bound radioactivity was
separated from unbound activity by centrifugation (2 min
10 000 g in an Eppendorf centrifuge). The remaining
pellet was washed twice with ice-cold Hepes buVer and
radioactivity remaining in the final pellet was counted in a
gamma counter. Specific binding was taken to be the total
bound activity minus the activity bound in the presence
of 1 µM unlabelled octreotide (Sandostatin; Novartis
Pharma, Basel, Switzerland) or somatostatin-28 (Bachem,
Bubendorf, Switzerland) respectively. As a positive control
for binding, cell membranes from the mouse pituitary cell
line AtT20 were included in each test.
Systemic administration of octreotide and monitoring of arthritis
The eVect of systemic administration of octreotide, a
long-acting somatostatin analogue, on adjuvant arthritis in
the rat was studied. Sandostatin-LAR, a slow-release
formulation of octreotide, was used. This formulation gives
a continuous release of octreotide for a period of 6 weeks
after s.c. injection.
One day prior to the induction of arthritis, ten rats were
injected s.c. in the dorsal neck region with a suspension
of Sandostatin-LAR (a gift from Novartis Pharma) in
standard injection vehicle (buVered sodium carboxyl-
methylcellulose), corresponding to 10 (experiments 1 and
2) or 30 mg/kg octreotide (experiment 3). Ten control rats
were injected with standard injection vehicle only. The
next day adjuvant arthritis was induced in all the rats as
described above. Disease course was monitored twice
weekly for 6 weeks by measuring the diameter of all four
paws using industrial callipers. The animals were weighed
once a week and their general appearance and behaviour
were monitored to assess their condition. Blood was
collected by orbital puncture on days 21 and 42 of the
experiment. The rats were killed by CO2 asphyxiation on
day 42.
Results
With a view to using rat adjuvant arthritis as an animal
model in which to study the role of sst in inflammation, we
determined the expression pattern of the five known sst
subtypes in the major lymphoid organs of the rat, using
RT-PCR.
In order to study mainly leukocytes, stromal com-
ponents were removed from the lymphoid organs under
study by passing them through nylon gauze. Other authors
have studied only whole organs of the rat (Bruno et al.
1993, Raulf et al. 1994).
The results of the RT-PCR studies are shown in
Table 1. The major sst subtypes expressed in rat leukocytes
were found to be sst3 and sst4. A very weak sst1 signal was
observed in spleen cells in some, but not all, experiments.
No expression of sst2 or sst5 was observed in any of the cell
populations, even after a repeat amplification. A ladder
pattern of amplification products was consistently observed
in the sst4 PCR of thymocytes, but hybridisation of a
Southern blot of the PCR gel with an sst4-specific probe
yielded only a single band of the expected size. The
sst4-specific band for the total lymph node and lymph node
non-adherent cell preparations was barely visible in the
ethidium bromide-stained gel, but could be visualised by
Southern blot hybridisation with an sst4-specific probe.
The pattern of expression of sst in rat leukocytes was
confirmed in splenocytes from other strains of rats (females:
Wistar, Brown Norway, Wag/Rij, Sprague–Dawley,
BuValo and Fisher F344). Again only sst3 and sst4 were
expressed, with occasionally a very weak sst1 signal (not
shown).
Receptor saturation curves
Receptor saturation experiments were carried out on
membrane preparations of splenocytes and thymocytes of
control Lewis rats using the radioligands [125I-Tyr0]-
somatostatin-28 and [125I-Tyr3]-octreotide. Kd values and
receptor densities were determined by Scatchard analysis
of the saturation curves.
No membrane binding of [125I-Tyr3]-octreotide was
found (not shown), but [125I-Tyr0]-somatostatin-28 bound
with a Kd of 0·5 and 0·3 nM for splenocytes and
thymocytes respectively. As a control for binding,
sst-positive AtT20 mouse pituitary tumour cells were
used (Kd=0·9 nM). The calculated numbers of binding
sites were 755, 492 and 2679 fmol/mg protein for spleno-
cytes, thymocytes and AtT20 cells respectively. Figure 1
shows the Scatchard plots for the binding of [125I-Tyr0]-
somatostatin-28.
Semi-quantitative comparison of sst3 expression
Limiting dilution RT-PCR was performed to semi-
quantitatively compare sst3 mRNA levels in splenocytes
Table 1 Sst subtype mRNAs in cells of the rat immune system:
summary of RT-PCR study
sst1 sst2 sst3 sst4 sst5
Source of leukocytes
Spleen & " + + "
Peripheral blood " " + + "
Thymus " " + & "
Lymph nodes " " + & "
Lymph nodes (non-adherent cells) " " + & "
+, visible on ethidium bromide-stained agarose gel; &, not visible, but
visualised by Southern blotting.
A M C TEN BOKUM and others · Somatostatin receptor subtypes in rat immune cells170
Journal of Endocrinology (1999) 161, 167–175
from CFA-injected rats with adjuvant arthritis (further
referred to as CFA-injected rats) and controls. Two-fold
serial dilutions of cDNA were titrated to give approxi-
mately equal â-actin signals and were then subjected to
PCR for sst3. The results are shown in Fig. 2. No
substantial diVerences in the amount of sst3 mRNA in
CFA-injected versus control rats could be demonstrated.
DiVerential expression of sst4 mRNA in leukocyte
subpopulations
Sst4 was expressed at levels readily detectable on ethidium
bromide-stained gels only in splenocytes and peripheral
blood, whereas expression in the other lymphoid cell
preparations was only detectable after Southern blotting.
This was true for both CFA-injected rats and control rats.
Peripheral blood and spleen, as well as peripheral lymph
nodes harbour large numbers of activated cells during
systemic inflammation. However, spleen and peripheral
blood contain a relatively larger proportion of monocytes
in addition to their lymphocytes. The diVerence observed
in sst4 expression levels between peripheral blood and
splenocytes on the one hand and lymph nodes on the other
hand, suggested that sst4 might be expressed by monocytes
and cells of the monocyte lineage such as dendritic cells. A
cell population enriched for dendritic cells, isolated from
the spleen of a normal Lewis rat, was found to express sst4
mRNA (not shown). We therefore set out to prepare,
from peripheral blood, a cell population enriched for
monocytes, using density centrifugation over Percoll. Sst3
and sst4 were expressed in the unseparated population and
also in both populations obtained after density centrifuga-
tion (not shown). The cellular composition of the diVerent
populations is summarised in Table 2.
Limiting dilution RT-PCR was carried out as described
above to semi-quantitatively compare the sst4 mRNA
expression in the diVerent populations. The results are
shown in Fig. 3. It was shown that the interphase cell
population had a relatively higher sst4 expression than
either the pellet population or total PBMCs. This was true
for both CFA-injected and control rats.
The eVect of systemic administration of octreotide on
adjuvant arthritis
We studied the eVect of systemic administration of
octreotide on the incidence and the severity of rat adjuvant
arthritis, as somatostatin has been shown to have beneficial
eVects in human rheumatoid arthritis (Coari et al. 1995).
Sandostatin-LAR was used in three separate experiments
(see Table 3). The data show that neither a low dose
(10 mg/kg) nor a higher dose (30 mg/kg) of Sandostatin-
LAR had an eVect on incidence and severity of the
arthritis.
Arthritis was confirmed histologically. Marginal erosion
of the bone and hyperplastic synovium extending into the
joint cavity was observed, with an infiltrate consisting
mainly of lymphocytes, polymorphonuclear cells and
histiocytes.
In the first experiment the octreotide levels in the
serum were determined on days 21 and 42. The mean
concentrations&s.e.m. were 2·353&0·641 and 1·524&
0·744 ng/ml respectively for the octreotide-treated group,
and undetectable (<0·1 mg/ml) for the control group.
Nine rats out of ten still had detectable serum levels of
octreotide on day 42. These data show that the octreotide
was released from the s.c. depot continuously throughout
the course of the experiment.
Discussion
Somatostatin is a ubiquitous neuropeptide with diverse
physiological functions. The recent cloning of a family of
sst and the demonstration that these receptors diVer
in their aYnities for synthetic somatostatin analogues
(Shimon et al. 1997) suggest that the diverse actions of
somatostatin might be mediated by diVerent receptor
subtypes.
We are interested in the immunomodulatory eVects of
somatostatin and somatostatin analogues. Because of the
up-regulation of sst expression in inflamed joints in human
rheumatoid arthritis, we chose rat adjuvant arthritis as an
Figure 1 Sst expression at the protein level in rat splenocytes and
thymocytes. Scatchard analysis of [125I-Tyr0]-somatostatin-28
binding to Lewis rat splenocytes and thymocytes and the
sst-positive mouse pituitary tumour cell line, AtT20. , AtT20 cells
(Kd=0·9 nM, n=2679 fmol/mg), . Lewis splenocytes (Kd=0·5 nM,
n=755 fmol/mg), 0 Lewis thymocytes (Kd=0·3 nM,
n=492 fmol/mg).
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experimental model. In order to determine which of the
sst subtypes might be important in immune modulation,
we studied the sst subtype expression in lymphoid tissues
and cells of the rat, using RT-PCR.
The main sst expressed in cells of the rat immune
system, both resting and activated, were found to be sst3
and sst4. This contrasts with the situation in humans and
mice, in which sst2 appears to be the main subtype
expressed in the immune system (Elliott et al. 1994, Van
Hagen et al. 1994a and unpublished observations).
Furthermore, our results indicate that sst4 is expressed
by distinct sub-populations of rat leukocytes. A peripheral
blood cell fraction enriched for monocytes showed an
increased sst4 expression. However, we were not able to
obtain a highly purified rat monocyte population using
density centrifugation. Flow cytometric analysis suggests
that, in contrast to what is seen in humans, rat PBMC
exhibit a wide range of sizes and densities, and cannot be
identified as a separate population in forward-sideward-
scatter plots (Scriba et al. 1996 and unpublished obser-
vations). The low-density cell population also contains
activated lymphocytes (lymphoblasts), leaving open the
possibility that sst4 mRNA is up-regulated upon acti-
vation. However, we found no quantitative diVerences in
Figure 2 Sst3 mRNA expression levels in rats with adjuvant arthritis and controls. For semi-quantitative
comparison of sst3 mRNA expression in splenocytes of Lewis rats with adjuvant arthritis (CFA-injected)
versus controls (IFA-injected), serial 2-fold dilutions of cDNA were subjected to PCR for â-actin and sst3.
Figure 3 Increased expression of sst4 mRNA in a population of rat peripheral blood cells enriched for monocytes. Subpopulations of
PBMC from Lewis rats with adjuvant arthritis (CFA injected) and controls (IFA injected) were prepared by density centrifugation over
Percoll. For semi-quantitative comparison of sst4 mRNA expression levels, serial 2-fold dilutions of cDNA were subjected to PCR for
â-actin and sst4. The cDNA samples in the â-actin panel of the figure are diluted 8-fold as compared with the corresponding samples in
the sst4 panel.
Table 2 Cellular composition (%) by nuclear morphology of the peripheral blood cell populations before and
after Percoll density centrifugation
CFA IFA
PMN Lymphocyte Monocyte PMN Lymphocyte Monocyte
PBMC 7 91 2 12 80 8
Percoll pellet 9 85 5 2 90 8
Percoll interphase 4 78 18 4 80 16
PMN, polymorphonuclear.
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sst subtype mRNA levels between CFA-injected rats with
adjuvant arthritis and control rats. This observation again
seems in contrast with the situation in the human immune
system in which binding sites for somatostatin seem to be
preferentially expressed on activated leukocytes (Van
Hagen et al. 1994a).
Our results on the sst subtype expression in rat spleno-
cytes contrast with the expression patterns found by others
in intact rat spleen. Raulf et al. (1994) detected sst3
mRNA but not sst4 mRNA in rat spleen and lymph
nodes. These authors also found a weak sst5 signal in the
spleen. However, this expression might be due to the
presence of stromal cells, e.g. nerves, which are largely
eliminated in our procedure of making cell suspensions.
Using a highly sensitive nuclease protection assay, Bruno et
al. (1993) found mRNA for all five sst subtypes in rat
spleen. It was clear from their results also that sst3 was the
main subtype in spleen, whereas the other four subtypes
showed much lower expression. Our results on the sst
subtype expression in rat thymocytes contrast with the
findings of Sedqi et al. (1996), who showed transcripts for
sst2 in resting and activated thymocytes and sst1 in
activated thymocytes, but who did not detect mRNA for
sst3. A contributing factor to the major discrepancy in
sst2 expression reported in the two papers could be the
fact that Sedqi et al. analysed cells from male rats, whereas
we used female rats on account of their susceptibility to
adjuvant arthritis. It is known that the expression of sst2
can be influenced by oestrogens, e.g. the transplantable rat
prolactin-secreting pituitary tumour 7315b expresses sst2
when grown in vitro, but loses this expression when grown
in vivo under the influence of circulating oestrogens
(Visser-Wisselaar et al. 1997). However, the diVerence in
expression of sst3 as determined in the study of Sedqi et al.
and in this study needs further investigation.
At the protein level, no binding of the sst2- and
sst5-selective radioligand [
125I-Tyr3]-octreotide was found.
This result was in accordance with the lack of sst2 and sst5
expression, as found by RT-PCR. Other studies have
generally found a good correlation between the presence of
octreotide binding sites and the presence of sst2 and/or sst5
mRNA (Reubi et al. 1996). The radioligand [125I-Tyr0]-
somatostatin-28 was bound, demonstrating the presence of
other subtypes of sst. We therefore conclude that the
mRNA for sst3 and sst4, which was detected by RT-PCR,
is functional, and can give rise to membrane expression of
sst proteins in rat leukocytes.
Finally, no therapeutic eVect of systemic administration
of octreotide, in the form of Sandostatin-LAR, was found
on the incidence and severity of adjuvant arthritis in Lewis
rats. This may be due to the absence in the immune system
of the rat of sst2 and sst5, which have a high aYnity for this
octapeptide somatostatin analogue. The absence of octreo-
tide binding sites in vitro is correlated with the absence of in
vivo biochemical response to octreotide, at least in the case
of hormone-secreting tumours (Reubi et al. 1990). Using a
diVerent somatostatin analogue, BIM23014 (1 µg/h; the
doses we used correspond to 2·5 and 7·5 µg octreotide/h),
Rees et al. (1989) did find a statistically significant decrease
in arthritis severity, although a diVerent measure of severity
was used. The eVect cannot be explained by diVerences in
binding profiles of octreotide and BIM23014 (Shimon et al.
1997) on the distinct sst subtypes (although to our knowl-
edge no comparisons of the binding profiles of these
compounds on the rat sst subtypes are available). Alterna-
tively, the somatostatin analogues might not have acted
directly on the immune cells in these studies, but might
have had a more generalised eVect through neuroendo-
crine mechanisms. However, no diVerences were found in
the eYcacies of octreotide and BIM23014 in inhibiting the
release of several hormones (Hofland et al. 1997, Shimon
et al. 1997).
In human rheumatoid arthritis the inflamed joints may
be visualised by in vivo scintigraphy using the sst2- and
sst5-selective somatostatin analogue [
111In-DTPA-d-
Phe1]-octreotide (Van Hagen et al. 1994c). In rat adjuvant
arthritis the aVected joints could not be visualised using
this analogue (Breeman et al. 1996), indicating that the
cells of the inflammatory infiltrate in the joint also lack the
sst subtypes (sst2 and sst5) which have a high aYnity for
octreotide. We recently showed the presence of sst2A in
endothelial cells and cells of the monocyte/macrophage
lineage in human rheumatoid synovium (ten Bokum et al.,
unpublished observations).
In conclusion, cells of the rat immune system appear to
express a spectrum of sst (sst3 and sst4) diVerent from that
Table 3 Effect of systemic administration of octreotide (as Sandostatin-LAR) on the incidence and severity of adjuvant arthritis in Lewis rats
Incidence Severity*
Sandostatin-LAR Controls P-value** Sandostatin-LAR Controls P-value**
Octreotide dose (mg/kg)
10 (experiment 1) 7/9 10/10 0·21 38·1&10·9 59·2&14·1 0·29
10 (experiment 2) 8/10 7/10 0·50 58·3&15·0 57·4&12·4 0·97
30 (experiment 3) 8/9 10/10 0·47 105·0&18·3 116·3&10·2 0·81
*Severity expressed as mean maximal increase in total paw diameter (in 0·1 mm)&S.E.M.
**Statistics: incidence was compared using a Fisher exact test. Severity was compared using a Mann–Whitney test (two-sided).
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found in human granulomatous and autoimmune diseases
(Van Hagen et al. 1994b,c). Therefore, the rat adjuvant
arthritis model appears to be suitable only for studying the
immunomodulatory eVects of somatostatin analogues
which have a high aYnity for sst3 and sst4, but not for
studying the immunomodulatory eVects of octreotide,
which has a high aYnity only for sst2 and sst5.
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